Editors:
Comprehensive focus on the folate receptor and its exploitation for targeted therapy and diagnostic imaging
Describes the boundaries between what’s considered to be “molecular targeted” versus conventional systemic therapy
Discussing discoveries that parallel the emergence of innovative “molecular targeted” small molecules and monoclonal antibodies, i.e. agents that target proteins within highly activated signal transduction pathways that control proliferation
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (12 chapters)
-
Front Matter
-
Back Matter
About this book
Folate pathways are essential in metabolism and macromolecule synthesis. Antifolate drugs that are largely transported via a high capacity folate transporter (i.e. the reduced-folate carrier) and inhibit folate-dependent enzymes include the dihydrofolate reductase inhibitor, methotrexate, and the thymidylate synthase inhibitors, raltitrexed and pemetrexed. Major advances in folate research made within the last decade include (i) the approval of pemetrexed for the treatment of lung cancer and mesothelioma, and (ii) the demonstration that cell membrane-anchored folate receptors (FR) are exploitable for cancer and inflammatory disease management. FRs are not widely distributed in normal tissues, except on some luminal surfaces; however, they are accessible to systemically administered agents when expressed on many cancers as well as on activated macrophages involved in various inflammatory diseases. High affinity folate-radioisotope conjugates have been developed for imaging pathogenic FR-positive diseases, including cancer. Since the FR transports folates via a low capacity but high affinity endocytic pathway, a variety of FR-targeted antifolate drugs and folate conjugates bearing a wide range of payloads (including cytotoxic drugs) are currently being developed which exploit this property. The FR is also being utilized in immunotherapy approaches for the treatment of overexpressing cancers.
Editors and Affiliations
-
Section of Medicine, Institute of Cancer Research, Sutton, United Kingdom
Ann L. Jackman
-
Endocyte Inc., West Lafayette, USA
Christopher P. Leamon
Bibliographic Information
Book Title: Targeted Drug Strategies for Cancer and Inflammation
Editors: Ann L. Jackman, Christopher P. Leamon
DOI: https://doi.org/10.1007/978-1-4419-8417-3
Publisher: Springer New York, NY
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer Science+Business Media, LLC 2011
Hardcover ISBN: 978-1-4419-8416-6Published: 06 May 2011
Softcover ISBN: 978-1-4899-8886-7Published: 01 October 2014
eBook ISBN: 978-1-4419-8417-3Published: 05 May 2011
Edition Number: 1
Number of Pages: XI, 254
Topics: Cancer Research, Pharmacology/Toxicology